|Bid||454.00 x 0|
|Ask||456.50 x 0|
|Day's range||446.50 - 462.00|
|52-week range||414.00 - 1,678.00|
|Beta (5Y monthly)||0.93|
|PE ratio (TTM)||1,973.91|
|Earnings date||20 Sept 2022 - 26 Sept 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1,341.17|
Oxford Biomedica (LON:OXB) has had a rough three months with its share price down 35%. However, stock prices are...
Oxford Biomedica plcPreliminary results for the year ended 31 December 2021 Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE: OXB), (“Oxford Biomedica” or “the Group”), a leading cell and gene therapy group, today announces its preliminary results for the year ended 31 December 2021. Dr. Roch Doliveux, Chair and Interim Chief Executive Officer of Oxford Biomedica, said: “I am delighted with our performance in 2021 which was a true testament to the hard work of all our employees
Investors dumped shares in the company on the back of the news, which sent it to the bottom of the FTSE 250.